BACKGROUND: Few studies have examined the effectiveness of full versus partial vaccination with inactivated trivalent influenza vaccines (IIV3) as defined by the US CDC Advisory Committee on Immunization Practices. METHODS: Respiratory swabs were collected from outpatients aged 6 months to 8 years with acute cough for ≤7 days in clinics in 5 states during the 2011-2012 and 2012-2013 influenza seasons. Influenza was confirmed by real-time reverse transcription polymerase chain reaction assay. Receipt of current season IIV3 and up to 4 prior vaccinations was documented from medical records and immunization registries. Using a test-negative design, vaccine effectiveness (VE) was estimated adjusting for age, race/ethnicity, medical conditions, study site and month of enrollment. RESULTS: We did not observe higher VE for children fully versus partially vaccinated with IIV3, as defined by US Advisory Committee on Immunization Practice, although our sample of partially vaccinated children was relatively small. However, among children aged 2-8 years in both seasons and against A(H3N2) and B influenza illness separately, VE point estimates were consistently higher for children who had received 2 doses in the same prior season compared with those without (VE range of 58%-80% vs. 33%-44%, respectively). Across seasons, the odds of A(H3N2) illness despite IIV3 vaccination were 2.4-fold (95% confidence interval: 1.4-4.3) higher among children who had not received 2 doses in the same prior season. We also noted residual protection among unvaccinated children who were vaccinated the previous season (VE range = 36%-40% across outcomes). CONCLUSION: Vaccination with IIV3 may provide preventive benefit in subsequent seasons, including possible residual protection if vaccination is missed. Two vaccine doses in the same season may be more effective than alternative priming strategies.
BACKGROUND: Few studies have examined the effectiveness of full versus partial vaccination with inactivated trivalent influenza vaccines (IIV3) as defined by the US CDC Advisory Committee on Immunization Practices. METHODS: Respiratory swabs were collected from outpatients aged 6 months to 8 years with acute cough for ≤7 days in clinics in 5 states during the 2011-2012 and 2012-2013 influenza seasons. Influenza was confirmed by real-time reverse transcription polymerase chain reaction assay. Receipt of current season IIV3 and up to 4 prior vaccinations was documented from medical records and immunization registries. Using a test-negative design, vaccine effectiveness (VE) was estimated adjusting for age, race/ethnicity, medical conditions, study site and month of enrollment. RESULTS: We did not observe higher VE for children fully versus partially vaccinated with IIV3, as defined by US Advisory Committee on Immunization Practice, although our sample of partially vaccinated children was relatively small. However, among children aged 2-8 years in both seasons and against A(H3N2) and B influenza illness separately, VE point estimates were consistently higher for children who had received 2 doses in the same prior season compared with those without (VE range of 58%-80% vs. 33%-44%, respectively). Across seasons, the odds of A(H3N2) illness despite IIV3 vaccination were 2.4-fold (95% confidence interval: 1.4-4.3) higher among children who had not received 2 doses in the same prior season. We also noted residual protection among unvaccinated children who were vaccinated the previous season (VE range = 36%-40% across outcomes). CONCLUSION: Vaccination with IIV3 may provide preventive benefit in subsequent seasons, including possible residual protection if vaccination is missed. Two vaccine doses in the same season may be more effective than alternative priming strategies.
Authors: Harish Nair; W Abdullah Brooks; Mark Katz; Anna Roca; James A Berkley; Shabir A Madhi; James Mark Simmerman; Aubree Gordon; Masatoki Sato; Stephen Howie; Anand Krishnan; Maurice Ope; Kim A Lindblade; Phyllis Carosone-Link; Marilla Lucero; Walter Ochieng; Laurie Kamimoto; Erica Dueger; Niranjan Bhat; Sirenda Vong; Evropi Theodoratou; Malinee Chittaganpitch; Osaretin Chimah; Angel Balmaseda; Philippe Buchy; Eva Harris; Valerie Evans; Masahiko Katayose; Bharti Gaur; Cristina O'Callaghan-Gordo; Doli Goswami; Wences Arvelo; Marietjie Venter; Thomas Briese; Rafal Tokarz; Marc-Alain Widdowson; Anthony W Mounts; Robert F Breiman; Daniel R Feikin; Keith P Klugman; Sonja J Olsen; Bradford D Gessner; Peter F Wright; Igor Rudan; Shobha Broor; Eric A F Simões; Harry Campbell Journal: Lancet Date: 2011-11-10 Impact factor: 79.321
Authors: Kathleen M Neuzil; Lisa A Jackson; Jennifer Nelson; Alexander Klimov; Nancy Cox; Carolyn B Bridges; John Dunn; Frank DeStefano; David Shay Journal: J Infect Dis Date: 2006-09-11 Impact factor: 5.226
Authors: Katherine A Poehling; Kathryn M Edwards; Marie R Griffin; Peter G Szilagyi; Mary A Staat; Marika K Iwane; Beverly M Snively; Cynthia K Suerken; Caroline B Hall; Geoffrey A Weinberg; Sandra S Chaves; Yuwei Zhu; Monica M McNeal; Carolyn B Bridges Journal: Pediatrics Date: 2013-01-06 Impact factor: 7.124
Authors: Astride Jules; Carlos G Grijalva; Yuwei Zhu; H Keipp Talbot; John V Williams; Katherine A Poehling; Sandra S Chaves; Kathryn M Edwards; William Schaffner; David K Shay; Marie R Griffin Journal: Pediatrics Date: 2014-12-08 Impact factor: 7.124
Authors: Anthony E Fiore; David K Shay; Penina Haber; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy J Cox Journal: MMWR Recomm Rep Date: 2007-07-13
Authors: Li Liu; Hope L Johnson; Simon Cousens; Jamie Perin; Susana Scott; Joy E Lawn; Igor Rudan; Harry Campbell; Richard Cibulskis; Mengying Li; Colin Mathers; Robert E Black Journal: Lancet Date: 2012-05-11 Impact factor: 79.321
Authors: Jessie R Chung; Brendan Flannery; Manjusha Gaglani; Michael E Smith; Evelyn C Reis; Robert W Hickey; Michael L Jackson; Lisa A Jackson; Edward A Belongia; Huong Q McLean; Emily T Martin; Hannah E Segaloff; Sara S Kim; Manish M Patel Journal: JAMA Pediatr Date: 2020-07-01 Impact factor: 16.193
Authors: Huiying Chua; Susan S Chiu; Eunice L Y Chan; Shuo Feng; Mike Y W Kwan; Joshua S C Wong; J S Malik Peiris; Benjamin J Cowling Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia Journal: JAMA Netw Open Date: 2018-10-05
Authors: Mbayame Nd Niang; Jonathan D Sugimoto; Aldiouma Diallo; Bou Diarra; Justin R Ortiz; Kristen D C Lewis; Kathryn E Lafond; M Elizabeth Halloran; Marc-Alain Widdowson; Kathleen M Neuzil; John C Victor Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079
Authors: Sarah A Buchan; Hannah Chung; Michael A Campitelli; Natasha S Crowcroft; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David Richardson; Susan E Richardson; Laura C Rosella; Andrew Simor; Marek Smieja; Dat Tran; George Zahariadis; Jeffrey C Kwong Journal: PLoS One Date: 2017-11-17 Impact factor: 3.240
Authors: Lauren C Ramsay; Sarah A Buchan; Robert G Stirling; Benjamin J Cowling; Shuo Feng; Jeffrey C Kwong; Bryna F Warshawsky Journal: BMC Med Date: 2017-08-21 Impact factor: 8.775
Authors: Melissa A Rolfes; Doli Goswami; Amina Tahia Sharmeen; Sultana Yeasmin; Nasrin Parvin; Kamrun Nahar; Mustafizur Rahman; Marion Barends; Dilruba Ahmed; Mohammed Ziaur Rahman; Joseph Bresee; Stephen Luby; Lawrence H Moulton; Mathuram Santosham; Alicia M Fry; W Abdullah Brooks Journal: Vaccine Date: 2017-10-31 Impact factor: 3.641